Apostolopoulos V, Pietersz G A, Loveland B E, Sandrin M S, McKenzie I F
Austin Research Institute, Heidelberg, Victoria, Australia.
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10128-32. doi: 10.1073/pnas.92.22.10128.
The induction of CD8+ cytotoxic T lymphocytes (CTLs) is desirable for immunization against many diseases, and recombinant-synthetic peptide antigens are now favored agents to use. However, a major problem is how to induce CTLs, which requires a T1-type response to such synthetic antigens. We report that T1-type (generating high CTL, low antibody) or T2-type (the reciprocal) responses can be induced by conjugation of the antigen to the carbohydrate polymer mannan: T1 responses are selected by using oxidizing conditions; T2 responses are selected by using reducing conditions for the conjugation. Using human MUC1 as a model antigen in mice, immunization with oxidized mannan-MUC1 fusion protein (ox-M-FP) led to complete tumor protection (challenge up to 5 x 10(7) MUC1+ tumor cells), CTLs, and a high CTL precursor (CTLp) frequency (1/6900), whereas immunization with reduced mannan-MUC1 FP (red-M-FP) led to poor protection after challenge with only 10(6) MUC1+ tumor cells, no CTLs, and a low CTLp frequency (1/87,800). Ox-M-FP selects for a T1 response (mediated here by CD8+ cells) with high interferon gamma (IFN-gamma) secretion, no interleukin 4 (IL-4), and a predominant IgG2a antibody response; red-M-FP selects for a T2-type response with IL-4 production and a high predominant IgG1 antibody response but no IFN-gamma.
诱导CD8+细胞毒性T淋巴细胞(CTLs)对于针对多种疾病的免疫接种而言是很有必要的,而重组合成肽抗原如今是常用的首选制剂。然而,一个主要问题是如何诱导CTLs,这需要对这类合成抗原产生T1型反应。我们报告称,通过将抗原与碳水化合物聚合物甘露聚糖偶联,可以诱导T1型(产生高CTL、低抗体)或T2型(相反情况)反应:通过使用氧化条件来选择T1反应;通过使用还原条件进行偶联来选择T2反应。以人MUC1作为小鼠模型抗原,用氧化甘露聚糖-MUC1融合蛋白(ox-M-FP)进行免疫接种可实现完全的肿瘤保护(可抵御高达5×10⁷个MUC1+肿瘤细胞的攻击)、产生CTLs以及高CTL前体(CTLp)频率(1/6900),而用还原甘露聚糖-MUC1融合蛋白(red-M-FP)进行免疫接种,在仅用10⁶个MUC1+肿瘤细胞攻击后保护效果不佳、未产生CTLs且CTLp频率低(1/87,800)。Ox-M-FP选择产生具有高干扰素γ(IFN-γ)分泌、无白细胞介素4(IL-4)且主要为IgG2a抗体反应的T1反应(此处由CD8+细胞介导);red-M-FP选择产生具有IL-4产生且主要为高IgG1抗体反应但无IFN-γ的T2型反应。